📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Tasigna (nilotinib) in chronic myeloid leukemia treatment-free remission after nearly 2 years: an interview with Adam Mead. (2017)

First Author: Mead A

Attributed to: Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.2217/fon-2017-0460

PubMed Identifier: 29124948

Publication URI: http://europepmc.org/abstract/MED/29124948

Type: Journal Article/Review

Volume: 13

Parent Publication: Future oncology (London, England)

Issue: 27

ISSN: 1479-6694